November 11, 2021
Icosavax to Participate in Upcoming Investor Conferences
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today
September 10, 2021
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel.
July 28, 2021
Icosavax Announces Pricing of Upsized Initial Public Offering
SEATTLE --(BUSINESS WIRE)--Jul. 28, 2021-- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today
June 10, 2021
Icosavax Appoints Thomas J. Russo Chief Financial Officer
SEATTLE, June 10, 2021 — Icosavax, Inc. today announced the appointment of Thomas J. Russo as Chief Financial Officer. Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst
June 8, 2021
Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate
First participants dosed in a Phase 1 clinical trial to assess safety and efficacy of IVX-411 with or without Seqirus Inc.’s proprietary adjuvant MF59® in subjects naïve to COVID-19 Phase 2 will evaluate safety and efficacy of adjuvanted or unadjuvanted IVX-411 as a booster in adults who have been